MGC Pharmaceuticals to buy Australia’s top medicinal cannabis clinic

By Nikita Chaurasia  Date: 2020-07-20

MGC Pharmaceuticals to buy Australia’s top medicinal cannabis clinic

As reported by credible sources, MGC Pharmaceuticals Ltd, a European bio-pharma firm, aims to acquire the complete data, intellectual property, and operating clinic-based assets of Medicinal Cannabis Clinic Pty Ltd.

As per the agreement, the new company, which will be incorporated to hold all assets of MCC, will attain pertinent state and federal licenses. This permit will further enable the import and supply of medicinal cannabis products. The company would be able to offer inexpensive cannabinoid through the focused reduction of import, storage, and distribution costs per unit.

For those uninitiated, MGC Pharma specializes in production and development of medicines which are EU-GMP Phyto cannabinoid derived. It has signed an agreement with Cannvalate Pty Ltd in a bid to acquire its wholly owned subsidiary MCC, which s has an extensive network of patients and doctors.

Speaking of the move, co-founder & MD of MGC Pharma, said that the acquisition of MCC assets is a vital part of their strategy to expand their direct supply chain capabilities and distribution network in Australia, and world over. He further added that the organization will achieve its cashflow breakeven goals through this acquisition. The company looks forward to integrating high-quality clinics network of MCC, he said.

MGC Pharma has reportedly decided to continue services of MCC staff to maintain the continuity of operations of the new firm, ensuring exceptional clinical governance and independence. The fundamental business ethos, product offering, and existing operations of MCC will remain unchanged.

If reports are to be believed, the deal includes USD 400,000 in cash and USD 1 million in MGC Pharma shares. The clearance of the transaction is projected to be concluded within 90 days.

Source- https://www.proactiveinvestors.com.au/companies/news/924532/mgc-pharmaceuticals-moves-to-acquire-one-of-australia-s-leading-medicinal-cannabis-clinics-924532.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

France might ban short domestic flights to reduce its carbon footprint

France might ban short domestic flights to reduce its carbon footprint

By Nikita Chaurasia

French lawmakers recently came to a unanimous decision to ban domestic flights for distances that can be covered by train in over two-and-a-half- hours. The country aims to impose these restrictions in an effort to reduce carbon emissions, even as th...

Kavak secures USD 485 million in funding, eyes Latin America expansion

Kavak secures USD 485 million in funding, eyes Latin America expansion

By Nikita Chaurasia

Kavak, a Mexico-based used-car platform, has reportedly reached a valuation of USD 4 billion after securing USD 485 million during a new funding round. This makes it the fastest-growing as well as the most valued company in Latin America. The latest...

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical t...

LinkedIn confirms launch of a social audio platform to rival Clubhouse

LinkedIn confirms launch of a social audio platform to rival Clubhouse

By Nikita Chaurasia

LinkedIn, the popular employment-oriented online service, has confirmed that it is testing a social audio experience in its app which could offer users with better connectivity in their networks. Although several social media giants such as Twitter ...

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

By Nikita Chaurasia

Pfizer Inc., an American multinational pharmaceutical corporation, has recently announced to have started the early phase trials for its oral antiviral drug for Coronavirus. The company revealed that first phase trials of the experimental drug, PF-07...